ANGPTL3与ANGPTL8双重调控低密度脂蛋白胆固醇水平
本研究通过小鼠肝脏灌注及Ldlr-/-模型,探讨ANGPTL3(A3)不同片段与ANGPTL8(A8)对脂蛋白代谢的调控。发现A8单独失活使LDL-C降低约20%,且依赖内皮脂酶和A3;最大抑制脂蛋白脂酶需A8与全长及N端A3共表达,而最佳抑制内皮脂酶仅需A8。A3与A8协同差异调节脂解,影响肝脏清除致动脉粥样硬化性ApoB脂蛋白。
要点
- A8失活降低LDL-C约20%,依赖内皮脂酶和A3表达。
- 最大抑制脂蛋白脂酶需A8及全长与N端A3片段共表达。
- 最佳抑制内皮脂酶需A8表达,不依赖A3裂解。
核心结论
- A8与A3协同差异调节脂蛋白脂酶和内皮脂酶介导的脂解,拮抗肝脏清除新分泌的致动脉粥样硬化性ApoB脂蛋白。
研究设计与样本
- 肝脏灌注研究比较有无A3小鼠分泌VLDL颗粒的数量和组成。
- 构建表达野生型A3、全长A3或N端A3片段(伴或不伴A8共表达)的Ldlr-/-小鼠,分析血浆脂质、A3/A8复合物及血管内脂酶活性。
- 辅以体外试验和结构建模评估A3单独或与A8复合对内皮脂酶的抑制。
主要发现
- A3失活不改变野生型或Ldlr-/-小鼠肝脏分泌VLDL的速率。
- A8单独失活使血浆LDL-C降低约20%,该效应依赖内皮脂酶和A3表达。
- 最大抑制脂蛋白脂酶需A8与全长A3及N端A3片段共表达,表明A3裂解与A8表达均必需。
- 最佳抑制内皮脂酶需A8表达,而非A3裂解。
临床怎么用
- A3靶向降脂治疗需考虑A3裂解状态及A8表达对脂蛋白脂酶和内皮脂酶抑制的差异影响。
- 双重靶向A3和A8策略可能用于治疗血脂异常和预防动脉粥样硬化性心血管疾病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inactivation of ANGPTL3 (angiopoietin-like protein 3; A3) is a proven therapeutic strategy for lowering plasma lipid levels independently of the low-density lipoprotein receptor, yet the optimal approach to inactivate A3 remains unclear. A3 is proteolytically cleaved and circulates as full-length, N-terminal, and C-terminal fragments. The specific contribution of each form of A3, and of its paralog, ANGPTL8 (angiopoietin-like protein 8; A8), in modulating circulating levels of ApoB (apolipoprotein B)-containing lipoproteins remain poorly defined. Clarifying these relationships will inform next-generation A3-directed therapies. METHODS: We performed liver perfusion studies to directly compare the number and composition of very-low-density lipoprotein particles secreted from mice with and without A3. To amplify effects on cholesterol metabolism, we generated Ldlr-/- mice expressing wild-type A3, full-length A3, or N-terminal A3 fragments, with or without coexpression of A8, and analyzed plasma lipids, circulating A3 and A8 complexes, and intravascular lipase activities. Complementary in vitro assays and structural modeling were used to assess relative endothelial lipase inhibition by A3 alone or in complex with A8. RESULTS: Liver perfusion studies revealed that A3 inactivation does not alter the rates of hepatic secretion of very-low-density lipoprotein in wild-type or Ldlr-/- mice. Inactivation of A8 alone lowered plasma low-density lipoprotein cholesterol levels by ≈20%, an effect dependent upon the expression of both endothelial lipase and A3. Maximal inhibition of lipoprotein lipase required coexpression of A8 plus both full-length A3 and N-terminal A3 fragments, indicating that A3 cleavage, in addition to A8 expression, is essential for maximal lipoprotein lipase inhibition. In contrast, A8 expression, but not A3 cleavage, was required for optimal endothelial lipase inhibition. CONCLUSIONS: A8 acts in concert with A3 to differentially modulate lipoprotein lipase- and endothelial lipase-mediated lipolysis, which antagonizes hepatic clearance of newly secreted atherogenic ApoB-containing lipoproteins. This mechanistic framework refines our understanding of A3-targeted lipid lowering and highlights the therapeutic potential of dual A3- plus A8-directed strategies to treat dyslipidemia and prevent atherosclerotic cardiovascular disease.
引用
- Xu Y, Luo F, Fletcher J, et al. Dual Control of Low-Density Lipoprotein Cholesterol Levels by ANGPTL3 and ANGPTL8. Circulation. 2026. PMID: 42866886. doi:10.1161/CIRCULATIONAHA.126.080412
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。